Suppression of inflammation by a synthetic histone mimic - Test2 - elhamkhani - TriplyDB

Suppression of inflammation by a synthetic histone mimic

Suppression of inflammation by a synthetic histone mimic

http://www.wikidata.org/entity/Q27665789

about

RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells Suppression of the antiviral response by an influenza histone mimic Histone recognition and large-scale structural analysis of the human bromodomain family Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition Small-molecule inhibition of BRDT for male contraception.Process of Fragment-Based Lead Discovery-A Perspective from NMR Chemical genetics approaches for selective intervention in epigenetics Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors Strategically targeting MYC in cancer The Interplay Between Monocytes/Macrophages and CD4(+) T Cell Subsets in Rheumatoid Arthritis Molecular control of activation and priming in macrophages Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy Manipulation of the host protein acetylation network by human immunodeficiency virus type 1 Histone modifications and a choice of variant: a language that helps the genome express itself Bromodomain proteins in HIV infection Preparing the first responders: building the inflammatory transcriptome from the ground up Design of small molecule epigenetic modulators Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma Regulation of type I interferon responses Anti-inflammatory therapy in chronic disease: challenges and opportunities Shining a light on intestinal traffic Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes Chromatin targeting drugs in cancer and immunity The bromodomain: from epigenome reader to druggable target Cancer epigenetics drug discovery and development: the challenge of hitting the mark Small molecules in the treatment of systemic lupus erythematosus Protein lysine acetylation by p300/CBP Bromodomain Proteins Contribute to Maintenance of Bloodstream Form Stage Identity in the African Trypanosome Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit Structural Conservation of Distinctive N-terminal Acetylation-Dependent Interactions across a Family of Mammalian NEDD8 Ligation Enzymes Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains

P2860

Q21132391-73CFD675-CE79-4F6B-A19D-E1F285A0DADE Q24293271-3E7B9E09-B8D7-479B-9530-CB8B2ECCA87F Q24301441-8D715715-FFF5-4603-A5CE-17E4DE41B84E Q24307599-67D7B16F-6E35-4AA9-BBFC-38747AC81C6B Q24310431-601DA7F3-8FDF-43E0-907C-C6F5D8BBD0D8 Q24315005-E19DA759-054F-444F-A813-992FA1527B35 Q24337006-532027BD-A254-4B46-91E8-027C2C76C6DF Q24616901-476C3D60-E933-4DA9-97C3-5D46ADAD3133 Q26738768-6356CE1C-7C71-42FB-BC83-DD9897C7A50A Q26740037-5C5F4571-BCD4-4B66-B054-2FB7D65D7F6F Q26744080-79617536-8913-45F3-87D3-A9778A347E86 Q26744268-CE0F6BD1-E290-4B79-A15D-6496DAD84D60 Q26747745-6A02C1DB-B16F-4748-A134-DE72BE2E2D9A Q26774681-6C4104F2-E873-46A1-A497-42609AF8E2F6 Q26774972-541CB7A4-EE9A-463D-9A49-CBB7978C0394 Q26783032-9A9D8442-8C31-4B9E-83E6-B9195EA8D9FC Q26795463-46662421-D179-48AD-8BAA-C011FB18CA1F Q26823316-189083A2-CD4C-4867-A256-7F8479DAD3F7 Q26829860-963D7099-6231-48A5-A21D-7CE8B27D07A0 Q26849425-B83B14C7-EED3-4A12-A3E2-62A281B08CDA Q26850027-68F32E74-ECEF-4612-9D3D-127A30B9C076 Q26851166-11EB0EE7-BEB0-4ED2-A20A-4115C64D9770 Q26853177-E65FFA33-BEC6-48F0-B11B-38C5913229E0 Q26860162-21465860-9ECB-429E-80F2-582DA0036980 Q26863227-863B5F36-F243-4D23-886F-8A928BCEE056 Q26996631-DC871822-587C-4745-8937-1668E208C9A9 Q26999888-7269963F-60EF-46B5-B17C-0BE0B74AEFCA Q26999935-33E7567F-9F68-4898-B364-EAB603A75CC4 Q27002333-8D53BA75-5588-41D4-A010-0DE4095A3C84 Q27010090-5979533F-51AF-4FBD-8197-940126719DDB Q27021749-D11FBB42-E4E3-4C29-A07E-937736A69E3F Q27345564-BEE2A305-FD5B-4050-BF4F-47061EC19FEC Q27674674-17065A1A-B21E-4C3B-B063-725EE90594A2 Q27674710-6F830166-573A-400E-9536-5E22E72D9A9F Q27675332-7A2DF5AD-7EB2-4882-81C4-1EDCD1FEE5AB Q27675927-DA5AF260-7351-49D4-906E-9DBB9DE5C330 Q27676915-08289910-138C-4B79-BD1E-99D07376A1C4 Q27679878-0EAC8C62-8510-4595-9E23-3DC2B0DFFA02 Q27680134-3ED702C6-2374-4CBA-9E91-DC31CE5B78B6 Q27680405-53A08916-F7C2-442F-97C1-A03C0F32F1FF

P2860

Suppression of inflammation by a synthetic histone mimic

http://www.wikidata.org/entity/Q27665789

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Suppression of inflammation by a synthetic histone mimic

@ast

Suppression of inflammation by a synthetic histone mimic

@en

Suppression of inflammation by a synthetic histone mimic

@nl

type

label

Suppression of inflammation by a synthetic histone mimic

@ast

Suppression of inflammation by a synthetic histone mimic

@en

Suppression of inflammation by a synthetic histone mimic

@nl

prefLabel

Suppression of inflammation by a synthetic histone mimic

@ast

Suppression of inflammation by a synthetic histone mimic

@en

Suppression of inflammation by a synthetic histone mimic

@nl

P1433

Q27665789-51B578BE-3E22-4C02-A165-A28574D2D0E1

P1476

Q27665789-36E8C227-1874-4569-B940-3D4E592A6B5A

P2093

Q27665789-04408511-F721-42DE-BD52-E07142A0B517

Q27665789-0B36A845-F82F-41BD-A1FD-B88C9C3D9B6F

Q27665789-154FCD34-BE04-46EF-8DF7-80F2D88D5BCC

Q27665789-2F8D5C8D-2596-43B1-9C03-C944F42AA6F8

Q27665789-3B0A4158-2902-4371-A5FE-29383A8240DB

Q27665789-45FF8C66-D3D3-44F3-AFA7-78C61DF255FA

Q27665789-5840B9B0-8472-4E7D-90DB-3B6FE0CEE8D5

Q27665789-58851432-19F9-41CC-B9A5-AAAAAAEB4EF9

Q27665789-58B935EE-6A13-4C3C-9EA2-9266DE98BDA0

Q27665789-79B17946-01AF-4BAD-90CE-5BF519061DFA

P2860

Q27665789-1751DB9D-1805-4EB5-8945-14070E5F4B90

Q27665789-1CBBF21D-F5B4-438E-9E35-874CB930DA3F

Q27665789-1E5707D0-3750-4FE8-B620-CA8D88801D67

Q27665789-271A7B68-FCEC-42A3-BD0C-425F1363232A

Q27665789-569F32E8-F644-43E9-924F-2C6DEEF39F41

Q27665789-5FFE6217-F732-4477-BF48-1E4D005C886D

Q27665789-6F0B3174-FFB3-41E5-8515-E4B180524CE8

Q27665789-72F9646F-E4D0-4EF3-B874-87BACCD385DF

Q27665789-77087F26-9FF8-4A50-9170-0D2E48FF9604

Q27665789-852963BE-B460-4422-8638-D801E1267950

P2888

Q27665789-F85765B7-5FD7-48BF-83BA-91989F8D47CF

P304

Q27665789-70CB1DF2-A413-469D-98C6-6FEF548684C3

P31

Q27665789-F36BBAFC-6958-4D77-8069-CFE1B281BF5F

P3181

Q27665789-6DB0EFF1-3208-4C19-85C3-47AB086ABFB7

P356

Q27665789-DF391243-873D-4B3A-81B1-C872AFD966B6

P407

Q27665789-2BD5137B-3D41-447A-B2D4-E979A9A28822

P433

Q27665789-9E991C37-762D-49C2-B8F7-0BC297C838D5

P478

Q27665789-58DDCE6F-51AC-47FD-95C1-8A0EA924C4A4

P50

Q27665789-1D01989A-B27B-40D6-894C-87DFC4A86CF0

P577

Q27665789-4311FBA1-AE56-4155-99B7-F1BD257D393E

P5875

Q27665789-29302689-CA13-40CF-BEEB-AA2E765FB7B5

P6179

Q27665789-7D292955-8CB1-4861-BDB3-3BA2994226BB

P698

Q27665789-56AF9191-BEC0-4374-81B8-198E26A7BBF6

P921

Q27665789-2816A5BA-26FE-45CD-ABCC-81008DAD95BC

P932

Q27665789-90462CFE-D80A-4E7B-8439-B3F0E9681D47

P3181

P356

P1433

P1476

Suppression of inflammation by a synthetic histone mimic

@en

P2093

Alexander Tarakhovsky

http://www.w3.org/2001/XMLSchema#string

Charles M Rice

http://www.w3.org/2001/XMLSchema#string

Chun-Wa Chung

http://www.w3.org/2001/XMLSchema#string

Edwige Nicodeme

http://www.w3.org/2001/XMLSchema#string

Hervé Coste

http://www.w3.org/2001/XMLSchema#string

Jorge Kirilovsky

http://www.w3.org/2001/XMLSchema#string

Jose M Lora

http://www.w3.org/2001/XMLSchema#string

Julia White

http://www.w3.org/2001/XMLSchema#string

Kate L Jeffrey

http://www.w3.org/2001/XMLSchema#string

Kevin Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Translating the Histone Code

Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription

The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription

Expression and characterization of recombinant human acyloxyacyl hydrolase, a leukocyte enzyme that deacylates bacterial lipopolysaccharides

Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways

Structures of the Dual Bromodomains of the P-TEFb-activating Protein Brd4 at Atomic Resolution

Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4

Distinct factors control histone variant H3.3 localization at specific genomic regions

Brd4 is required for recovery from antimicrotubule drug-induced mitotic arrest: preservation of acetylated chromatin

P2888

P304

1119-23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

990749

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE09589

http://www.w3.org/2001/XMLSchema#string

P407

P433

7327

http://www.w3.org/2001/XMLSchema#string

P478

468

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47742949

http://www.w3.org/2001/XMLSchema#string

P6179

1049984554

http://www.w3.org/2001/XMLSchema#string

P698

21068722

http://www.w3.org/2001/XMLSchema#string

P921

P932

5415086

http://www.w3.org/2001/XMLSchema#string